Q-omics provides the consensus-scored PMS2P6 profile across patient tissues and cancer cell-line models. PMS2P6 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, PMS2P6 is differentially expressed in 4, with the highest sampling consensus in HNSC. Additionally, PMS2P6 RNA expression shows 14,354 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRP, HNSC, and ACC as cancer lineages where PMS2P6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PMS2P6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PMS2P6 survival associations across molecular data types. PMS2P6 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PMS2P6 RNA expression–survival associations across cancer types. High PMS2P6 expression shows unfavorable associations in ACC and KICH, but favorable associations in KIRP, THYM, HNSC and BRCA. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .005). Together, the overview and detailed table identify KIRP as the clearest survival context for PMS2P6 RNA expression.
This table summarizes PMS2P6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for PMS2P6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PMS2P6 shows higher tumor expression in HNSC, LUSC, KIRP and LIHC. The HNSC box plot shows higher PMS2P6 RNA expression in tumor versus normal tissue (log2 FC = +0.277, t-test p = .019).
This table shows molecular features associated with PMS2P6 in patient tissues and cancer cell lines. In patient samples, PMS2P6 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
